65 Researchers have been investigating the use of focused ultrasound (FUS) as a novel approach to delivering immunotherapy for brain cancer patients, potentially revolutionising treatment options for both primary and metastatic tumours. This non-invasive technique, combined with microbubbles, opens the blood-brain barrier (BBB) to enhance the delivery of immunotherapeutic agents directly to the brain. The findings, published in the Journal of Controlled Release, have raised hopes of improving outcomes for patients with conditions like glioblastoma, one of the most aggressive brain cancers. The blood-brain barrier, while crucial for protecting the brain from harmful substances, poses significant challenges for treating brain tumours. Its selective permeability often prevents traditional therapies from effectively reaching the tumour. FUS, however, temporarily disrupts this barrier, allowing targeted agents to penetrate. Preclinical studies have demonstrated that this method not only facilitates drug delivery but also stimulates immune responses within the tumour microenvironment, creating a multi-faceted attack on cancer cells. Glioblastoma, which accounts for the majority of malignant brain tumours, has a notoriously low survival rate, with patients typically living only 12–14 months after diagnosis despite aggressive treatment. Standard therapies include surgery, chemotherapy, and radiotherapy, but their efficacy is limited due to the cancer’s highly invasive nature. FUS offers a promising alternative by enabling the delivery of immunotherapy, which has shown success in treating other cancers but struggles to overcome the BBB in brain applications. The application of FUS involves the use of sound waves to create a focused acoustic field. Microbubbles, injected into the bloodstream, oscillate in response to the ultrasound, temporarily disrupting the BBB without causing significant harm to surrounding tissues. This approach has been used to deliver various agents, including monoclonal antibodies, immune cells, and cytokines, all of which play critical roles in modern immunotherapy. Notably, recent studies have demonstrated enhanced tumour cell targeting and increased immune cell infiltration, both essential for effective treatment. Current research highlights the adaptability of FUS across different tumour types. In glioblastoma models, the technique has shown potential in delivering checkpoint inhibitors, which help restore the immune system’s ability to attack cancer cells. For metastatic brain cancers, such as those originating from breast or lung tumours, FUS has been instrumental in delivering antibodies and immune-modulating agents, improving their concentration in the tumour microenvironment. Although promising, FUS is not without challenges. Ensuring precise targeting and minimising off-target effects remain critical areas of focus. Additionally, integrating FUS into clinical practice requires further validation through large-scale clinical trials. However, advancements in imaging and monitoring technologies are likely to accelerate the transition from experimental models to widespread application. The implications of FUS extend beyond oncology. Researchers are exploring its use in treating neurological conditions, including Alzheimer’s disease, where drug delivery across the BBB is similarly restricted. If successful, the technique could redefine therapeutic strategies for various brain disorders, potentially benefiting millions worldwide. As FUS research progresses, it could mark a turning point in the battle against brain cancer, offering hope to patients and clinicians alike by addressing some of the most significant barriers in treatment.